Vexim, a French company focused on the minimally invasive treatment of vertebral fractures, has announced the acquisition of an innovative technological system in the injection of orthopedic cement for its development in vertebroplasty. The system was developed by Altavance, a Swiss company.
Thanks to the acquisition of a brand new system for mixing and injecting orthopedic cement that complements the company’s SpineJack technology, Vexim is expanding its presence in the field of vertebroplasty. This new system will allow surgery to be performed on indications where priority is given to stabilizing the fracture and eliminating pain by injecting cement into the vertebra.
The company indicates the following advantages to this innovation:
- compatibility with the use of ultra‐high‐viscosity cement, thus limiting the risk of leakage and allowing controlled cement distribution in the vertebra;
- precision injection: control and immediate stop of the injection;
- safe and secure technique: the physician has better control when carrying out the injection while maximizing the radiation safety distance;
- user friendly: an injection system with increased strength that can be manipulated with one hand.
Simultaneously to its European launch in 2014, Vexim is considering introducing this unique system in the U.S. market. This innovative system thus provides a real opportunity to access one of the world’s largest markets.
Thanks to this positioning on the vertebroplasty segment and its exclusive vertebral restoration solution using the SpineJack, Vexim will have a comprehensive offer in the innovative treatment of vertebral fractures, a dynamic market that is expected to see double-digit growth over the coming years. Vexim intends to meet these growing needs by pursuing its innovation and marketing efforts in relation to its avant‐garde solutions, the aim being to eventually become the European leader in innovative back microsurgery.
Vincent Gardès, CEO of Vexim, commented in the February 28, 2013 news release, “At the time of our IPO almost a year ago, as a young innovative company in the minimally‐invasive spine surgery area, we pledged to become even more innovative every year in order to continually strengthen our competitive advantage. Thanks to this new solution in the field of vertebroplasty, we are proving that innovation is the driving force behind our development and the cornerstone of our continued growth.”
Asked what it will take for the company to enter the U.S. market, Gardès told OTW, “This product will be 510(k) exempt. VEXIM will sell this product through local distributors.”
